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Abstract
Background: Previously, we have examined the methylation status of SLC19A3 (solute carrier family 19, member 3)
promoter and found that SLC19A3 was epigenetically down-regulated in gastric cancer. Here, we aim to develop a new
biomarker for cancer diagnosis using methylated SLC19A3 DNA in plasma.
Methodology/Principal Findings: SLC19A3 gene expression was examined by RT-qPCR. Methylation status of SLC19A3
promoter was evaluated by methylation-specific qPCR. SLC19A3 expression was significantly down-regulated in 80% (12/15)
of breast tumors (P,0.005). Breast tumors had significant increase in methylation percentage when compared to adjacent
non-tumor tissues (P,0.005). A robust and simple methylation-sensitive restriction enzyme digestion and real-time
quantitative PCR (MSRED-qPCR) was developed to quantify SLC19A3 DNA methylation in plasma. We validated this
biomarker in an independent validation cohort of 165 case-control plasma including 60 breast cancer, 45 gastric cancer
patients and 60 healthy subjects. Plasma SLC19A3 methylated DNA level was effective in differentiating both breast and
gastric cancer from healthy subjects. We further validated this biomarker in another independent blinded cohort of 78
plasma including 38 breast cancer, 20 gastric cancer patients and 20 healthy subjects. The positive predictive values for
breast and gastric cancer were 90% and 85%, respectively. The negative predictive value of this biomarker was 85%.
Elevated level in plasma has been detected not only in advanced stages but also early stages of tumors. The positive
predictive value for ductal carcinoma in situ (DCIS) cases was 100%.
Conclusions: These results suggested that aberrant SLC19A3 promoter hypermethylation in plasma may be a novel
biomarker for breast and gastric cancer diagnosis.
Citation: Ng EKO, Leung CPH, Shin VY, Wong CLP, Ma ESK, et al. (2011) Quantitative Analysis and Diagnostic Significance of Methylated SLC19A3 DNA in the
Plasma of Breast and Gastric Cancer Patients. PLoS ONE 6(7): e22233. doi:10.1371/journal.pone.0022233
Editor: Alfons Navarro, University of Barcelona, Spain
Received November 1, 2010; Accepted June 22, 2011; Published July 18, 2011
Copyright:  2011 Ng et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The University of Hong Kong Seed Fund for Basic Research 2009 (Ref #: 10400959). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: akwong@asiabreastregistry.com
. These authors contributed equally to this work.
Introduction
Epigenetic changes, such as DNA methylation, are one of the most
common molecular alterations in human cancer [1], including gastric
[2] and breast cancer [3]. Emerging studies have shown that tumor-
specific epigenetic alterations of DNA can be detected from plasma or
serum of patients with various malignancies [4,5,6]. It has been
reported that breast cancer patients contained approximately 4 times
more cell-free DNA in serum compared with that of healthy
individuals [7]. Recent study has also demonstrated that hypermethy-
lation of RASSF1A DNA in serum is detected in gastric cancer [8]
and is associated with a worse outcome in breast cancer patients [9].
The promising results of these studies predict that such circulating
markers are likely to be identified with improved diagnostic sensitivity
and specificity for cancer. In particular, SLC19A3 (solute carrier
family 19, member 3 or THTR-2, thiamine transporter-2) which has
been found to be down-regulated in gastric and breast cancer
[10,11,12], could be a potential candidate for this diagnostic purpose.
SLC19A3 as well as SLC19A2 (solute carrier family 19, member 2 or
THTR1, thiamine transporter-1) are the carriers responsible for the
transportation of thiamine across the plasma membrane [13,14,15].
Like folate and many other water-soluble micronutrients, thiamine
was transported across the plasma membrane via a specialized carrier-
mediated mechanism. It has been recognized for a long time that
thiamine deficiency frequently occurs in cancer patients [16].
Previously, we showed that SLC19A3 but not SLC19A2 was
frequently down-regulated through promoter hypermethylation in
gastric cancer [10]. In the present study, we hypothesized that
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for cancer detection. Thus, we developed a simple methylation-
sensitive restriction enzyme digestion and real-time quantitative PCR
(MSRED-qPCR) assay to quantify SLC19A3 DNA promoter
methylation in plasma. The objective was to apply such SLC19A3
MSRED-qPCR to investigate the possibility of using such marker as a
novel diagnostic marker for breast and gastric cancer.
Materials and Methods
Ethics statement
The study was performed in accordance to the Declaration of
Helsinki. Written informed consent was obtained from all
participants involved in this study. This study was approved by
the Institutional Review Board of The University of Hong Kong/
Hospital Authority West Cluster, Hong Kong.
Study design and patients
A total of 259 participants were recruited in this study from
December 2008 through September 2010. Primary breast cancer
and their paired non-tumor breast tissues were collected from 15
breast cancer patients. Plasma samples from 98 breast cancer, 65
gastric cancer and 80 healthy subjects were collected for
biomarker validation. Biomarker validation consisted of two
phases: (i) Phase I validation: an independent validation cohort
of 165 case-control plasma samples including 60 breast cancer, 45
gastric cancer patients and 60 healthy subjects; (ii) Phase II
validation: another independent blinded validation cohort of 78
plasma samples including 38 breast cancer, 20 gastric cancer
patients and 20 healthy subjects. All samples were collected from
patients who underwent surgical resection of tumors. Tissue
samples were collected, stabilized with Tissue Stabilization
solution (Applied Biosystems), and stored at 280uC. All tumors
had been histologically confirmed. Tumors were staged according
to the tumor-node-metastasis (TNM) staging system. Informed
consent was obtained from all participants. This project was
approved by the Institutional Review Board of The University of
Hong Kong/ Hospital Authority West Cluster, Hong Kong.
RNA Extraction and Real-time qRT-PCR
Total RNA was extracted from tissue using Trizol reagent
(Invitrogen) according to the manufacturer’s instructions. 0.5 mgo f
total RNA was reversely transcribed into cDNA with High
Capacity cDNA Reverse Transcription kit (Applied Biosystems).
Real-time qPCR was performed using QuantiTect SYBR Green
PCR Kit (Qiagen) in ABI PRISM 7900 HT system (Applied
Biosystems). As previously described [10], primers used for
SLC19A3 gene expression were: Forward, 59-TTCTCCATGAT-
GAGACCCTC and Reverse, 59-ATGATGACTGGCTTGTAG-
CG. The expression levels of SLC19A3 mRNA were normalized
to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Fold
change of SLC19A3 expression was calculated by the equation
2
2DDCt. DCt was calculated by subtracting the Ct values of
GAPDH from the Ct values of SLC19A3. DDCt was then
calculated by subtracting DCt of the control from DCt of breast
cancer. Real-time qPCR was performed in triplicate.
Bisulfite Treatment of DNA and Methylation-Specific
qPCR
Tissue DNAs were extracted using QIAmp DNA Mini Kit
(Qiagen) following the manufacturer’s instructions. Genomic DNA
(500 ng) extract from tissue was bisulfite-treated with EpiTect
Bisulfite Kit (Qiagen) according to the protocol provided. Methyl-
ation-specific qPCR was carried out with 2 mlo fb i s u l f i t e - t r e a t e d
DNA using QuantiTect SYBR Green PCR Kit (Qiagen) in ABI
PRISM 7900 HT system (Applied Biosystems) according to the
manufacturer’s instructions. As previously described [10], methyla-
tion-specific primers were: SLC19A3-mF, 59-TTGGATTTATTC-
GATAGTCGC and SLC19A3-mR: 59-CCAACACGCGAAC-
TACGACG, and unmethylation specific primers were: SLC19A3-
uF, 59-TGTTTGGATTTATTTGATAGTTGT and SLC19A3-
uR, 59-CCCAACACACA AACTACAACA. qPCR was performed
using QuantiTect SYBR Green PCR Kit (Qiagen) in ABI PRISM
7900 HT system (Applied Biosystems). Percentage of methylation in
tissue samples was calculated by the following equation: % meth
=100/[1+2
DCt(meth-unmeth)]% [17]. DCt(meth-unmeth) was calculated
by subtracting the Ct values of methylated SLC19A3 signal from the
Ct values of umnethylated SLC19A3 signal. Each sample is run in
duplicates for analysis.
Plasma DNA extraction and MSRED-qPCR
Plasma from blood samples was processed and stored as
described previously [18]. Plasma DNAs were extracted using
QIAmp DNA Blood Mini kit (Qiagen), as previously described
[19,20] with modifications. In brief, 600 ml of plasma was used and
DNA was eluted with 40 ml of DNase-free water. 30 ml of extracted
plasma DNA was digested in a 40 ml reaction volume with 30 U of
methylation-sensitive restriction enzyme, BstU1 (New England
BioLabs), at 60uC for 16 hours. To ensure complete enzyme
digestion,itwasruninparallel with a positiveand a negativecontrol
digestion in which 30 ng of completely methylated or unmethylated
control DNA (EpiTect Control DNA, Qiagen) was digested. After
digestion, same amount of digested or undigested plasma DNA
along with control digestion was subjected to qPCR using
QuantiTect SYBR Green PCR Kit (Qiagen) in ABI 7900 HT
system (Applied Biosystems). Each reaction is performed in a final
volume of 20 ml containing digested (1.3 ml) or undigested (1 ml)
plasma DNA, 500 nM each primer and 16 SYBR Green PCR
Master mix (Qiagen). At the end of the PCR cycles, melting curve
analyses are performed to validate the specific PCR product.
Primers used for this qPCR were: Forward, 59-CCGCGTGCTG-
GGATTC and Reverse, 59-TCCAGAAGGCTGCAAATGG.
Relative expression level of plasma methylated SLC19A3 DNA
was expressed as 2
DCt(undigest-digest). DCt(undigest-digest) was calculated
by subtracting the Ct values of digested plasma DNA from the Ct
values of undigested plasma DNA. Since Ct of undigest should be
#Ct of digest, the expression level ranges from 1 to 0. Each sample
is run in duplicates for analysis. For 100% digestion efficiency,
relative expression level of completely unmethylated control DNA
(2
DCt(CTRLundig-CTRLdig)) must be close to zero whereas the level of
completely methylated control must be 1.
Statistical analysis
T h es i g n i f i c a n c eo fp l a s m al e v e lo fm e t h y l a t e dD N Aw a s
determined by Mann-Whitney test. The significance of SLC19A3
gene expression between tumor tissues and their paired adjacent non-
tumor was determined by Wilcoxon test. Correlation analysis
between SLC19A3 gene expression and methylation percentage
was determined by Spearman rank. The ROC value, sensitivity and
specificity were calculated according to the standard formulas. All P-
valuesare two-sided and ,0.05 wasconsidered statisticallysignificant
by GraphPad PRISM 4 software (GraphPad Software, La Jolla, CA).
Results
Patient characteristics
Patient characteristics and distribution of tumor stages were
summarized in Table 1. There were no significant differences of
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gastric cancer patients (mean, 62 years, SD=8.9), healthy controls
(mean, 57 years, SD=6.5).
SLC19A3 is frequently down-regulated through
promoter hypermethylation in breast cancer
To examine the expression level of SLC19A3 gene, we
performed qRT-PCR on 15 pairs of primary breast cancer tumor
tissues and their adjacent non-tumor breast tissues from 15
Chinese female breast cancer patients. Our results showed that
SLC19A3 mRNA level was significantly decreased in 12 of 15
(80%) breast cancer tumor tissues when compared to their
adjacent non-tumor breast tissues (fold change ranging from 22
to 250, P,0.005; Wilcoxon paired test; Figure 1). To investigate
whether down-regulation of SLC19A3 expression is associated
with hypermethylation of SLC19A3 promoter CpG islands, we
performed methylation-specific qPCR on those 15 pairs of
primary breast cancer tumor tissues and their adjacent non-tumor
breast tissues using primers targeting on a hypermethylated
promoter CpG region as previously studied [10]. Our data
revealed that those breast tumors had significant increase in
methylation percentage when compared to adjacent non-tumor
breast tissues (P,0.005; Wilcoxon paired test; Figure 2). Spearman
rank correlation showed that fold changes between SLC19A3
mRNA expression and methylation percentage were negatively
correlated (R
2=20.77, P,0.0005; Figure 3).
Phase I validation: Quantitative analysis of methylated
SLC19A3 DNA in the plasma of breast and gastric cancer
patients
Plasma level of methylated SLC19A3 DNA was assessed on a
group of 165 plasma samples including 60 breast cancer patients,
45 gastric cancer patients and 60 healthy controls. Our results
showed that methylated SLC19A3 DNA in plasma was signifi-
cantly higher in both gastric and breast cancer patients than those
of controls (All P-values,0.0001; Mann-Whitney U test; Figure 4).
To examine whether those markers are gender specific, plasma
levels of methylated SLC19A3 DNA were compared between the
female and male healthy in both gastric cancer group and control
group. Our data indicated similar plasma levels of this marker
(P=0.344 for gastric cancer, P=0.467 for controls; Mann-
Whitney U test) between female and male, suggesting their
expressions are not gender specific.
Phase II validation: Blinded analysis of breast and gastric
cancer samples
In this blinded validation phase, plasma level of this biomarker
was assessed on a blinded cohort of 78 plasma samples including
38 breast cancer patients, 20 gastric cancer patients and 20 healthy
controls. Our results showed that the positive predictive values for
breast and gastric cancer were 90% and 85%, respectively. The
negative predictive value of this marker was 85%. For breast
cancer, this marker yielded ROC value of 89% (Std. error=0.044,
Table 1. Patient characteristics.
Breast cancer (n=98) Gastric cancer (n=65) Healthy Control (n=80)
Characteristic No. of patients No. of patients No. of patients
Age (years)
Mean 58 62 57
Median (range) 61 (37–80) 60 (31–80) 59 (39–65)
Gender
Male 0 32 34
Female 98 33 46
TNM stage
*DCIS 27 - -
I 3 01 2-
II 27 7 -
III 13 19 -
IV 1 27 -
*DCIS, Ductal carcinoma in situ.
doi:10.1371/journal.pone.0022233.t001
Figure 1. Down-regulated SLC19A3 gene expression in primary
breast cancer tissues. Relative SLC19A3 mRNA expression between
tumor tissues and their paired adjacent non-tumor breast from breast
cancer patients (n=15) by real-time qPCR. Expression of SLC19A3
mRNA (Log10 scale at Y-axis) was normalized to GAPDH. The lines inside
the boxes denote the medians. The boxes mark the interval between
the 25
th and 75
th percentiles. The whiskers denote the interval between
the 10
th and 90
th percentiles. Statistical difference was analyzed by
Wilcoxon test, P,0.005.
doi:10.1371/journal.pone.0022233.g001
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was 87% (95% CI=71.9% to 95.6%) and specificity was 85%
(95% CI=62.1% to 96.8%). For gastric cancer, this marker
yielded a ROC value of 82% (Std. Error=0.073, 95% CI=68.0%
to 96.5%). At a cutoff point of 0.41, sensitivity was 85% (95%
CI=62.1% to 96.8%) and specificity was 85% (95% CI=62.1%
to 96.8%) (Figure 5A and 5B). To examine whether the plasma
levels of methylated SLC19A3 DNA may be associated with stages
of the disease, patients from both Phase I and II validations were
stratified based on the diagnosis of TNM staging. Of all gastric and
breast cancer patients, plasma levels did not vary significantly
across stage of the patients (P=0.149 for breast cancer, P=0.826
for gastric cancer; Kruskal-Wallis test). However, significant
differences were obtained when individual tumor stage including
early stage was compared with the controls, (All P-values,0.05;
Mann-Whitney U test; Figure 6A and 6B). Intriguingly, of all
DCIS cases (n=27) from breast cancer patients this plasma
marker generated positive predictive value of 100% at the cutoff of
0.41.
Discussion
In our previous study of gastric cancer, we showed that
SLC19A3 but not SLC19A2 was down-regulated through
promoter hypermethylation [10]. In this study, we further
confirmed that frequent down-regulation of SLC19A3 expression
in breast cancer is associated with hypermethylation of its
promoter CpG region. To explore the possibility of using this
methylated SLC19A3 DNA as a marker for breast cancer
detection, we developed a robust and simple methylation-sensitive
restriction enzyme-based quantitative assay to measure methylated
SLC19A3 DNA in plasma. Our results showed that plasma level of
methylated SLC19A3 DNA was significantly elevated in breast
cancer patients compared with those of controls. In the blinded
validation, our results showed that the positive predictive values
for breast and gastric cancer were 90% and 85%, respectively.
The negative predictive value of this marker was 85%. At a cutoff
point of 0.41 (relative plasma level of methylated SLC19A3 DNA),
the sensitivity was 87% and the specificity was 85% in
discriminating breast cancer from control subjects. At a cutoff
point of 0.41, the sensitivity was 85% and the specificity was 85%
in discriminating gastric cancer from control subjects. Intriguingly,
at a cutoff of 0.41, the positive predictive value of this biomarker
was 100%, which are reasonably good to discriminate early stage
DCIS cases from healthy controls. Although this finding suggests
plasma level of methylated SLC19A3 may serve as an early
diagnostic marker for breast cancer, further validations in larger
DCIS cohorts are necessary.
It has been recognized for a long time that thiamine deficiency
frequently occurs in cancer patients [16]. Notably, recent study
showed that SLC19A3 but not SLC19A2 deficiency in mice leads
to an impairment in intestinal thiamin uptake and a decrease in
blood thiamin levels, suggesting an important role of SLC19A3 in
thiamine regulation [21]. SLC19A3 down-regulation frequently
occurred in cancers including breast cancer [11,12]. Thus,
Figure 2. Increased percentage of SLC19A3 DNA methylation
in primary breast cancer tissues. Percentage of SLC19A3 promoter
methylation between tumor tissues and their paired adjacent non-
tumor breast tissues from the 15 breast cancer patients by MS-qPCR.
Percentage of methylation in tissue samples was calculated by the
following equation: % meth=100/[1+2
DCt(meth-unmeth)]%. DCt(meth-un-
meth) was calculated by subtracting the Ct values of methylated
SLC19A3 signal from the Ct values of umnethylated SLC19A3 signal.
Statistical difference was analyzed by Wilcoxon test, P,0.005.
doi:10.1371/journal.pone.0022233.g002
Figure 3. SLC19A3 is frequently down-regulated through
promoter hypermethylation in breast cancer. (A) Fold change
relationship between SLC19A3 mRNA expression and methylation
percentage in those 15 breast cancer patients (mean 6 SD). (B)
Correlation analysis of the fold changes between SLC19A3 mRNA
expression and methylation percentage (Spearman rank correlation,
R
2=20.77, P,0.0005).
doi:10.1371/journal.pone.0022233.g003
Plasma Methylated SLC19A3 DNA in Cancer
PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e22233SLC19A3 might function as a novel candidate tumor suppressor
gene in cancers. Previously, we are the first to report SLC19A3 is
epigenetically silenced in human cancers [10]. Here we
demonstrate the potential usefulness of methylated SLC19A3
DNA in plasma for cancer detection. Importantly, elevation of
plasma methylated SLC19A3 DNA level has been detected in not
only advanced stages but also pre-cancerous DCIS and early
stages of tumor suggesting a potential marker for early breast and
gastric cancer detection. These results show that hypermethyla-
tion of SLC19A3 promoter occurred in the earliest form of
cancer.
Instead of using bisulfite modification, we applied MSRED-
qPCR. This technology replaces the tedious and low-throughput
bisulfite-based methods with a simple restriction enzyme digest
and qPCR. DNA methylation-sensitive restriction enzyme is used
to selectively digest unmethylated DNA. The remaining DNA
after digestion or without digestion is quantified by qPCR using
primers flanking the hypermethylated SLC19A3 promoter CpG
region. Using this methodology, we can quantify any particular
CpG island by simply designing a pair of primers flanking
particular region of interest. Unlike bisulfite modification,
MSRED is a simple and specific enzyme digestion and
subsequent qPCR is performed without DNA purification. This
makes methylated DNA in plasma easily detectable. Further-
more, the same primer pair is used to amplify the digests and
undigests allowing the PCR results to be reliably and directly
compared. In contrast, bisulfite modification-based PCR methods
use two different pairs of primers to amplify either methylated or
unmethylated templates of a given target sequence. Differences in
their amplification efficiencies could cause biased results, and thus
requires normalization to methylated reference DNA. Historical-
ly, the digestion method has been problematic due to incomplete
digestion causing falsely high methylation results. In this regards,
incomplete digestion could be eliminated because our protocol
used an excess of restriction enzyme and a sufficient incubation
time relative to the recommended DNA amounts. Furthermore,
control DNA digestion was included to ensure the completeness
of digestion in the samples.
Although our results are promising, the sample size is still
small. Thus, further validations in large cohorts are necessary.
The reliability, simplicity and quantitative nature of this assay
make this technology an ideal tool for biomarker development in
human cancers. In the future, the combination of other potential
markers may further improve the discriminating power of this
test.
Figure 4. Quantitative analysis of plasma methylated SLC19A3
DNA on a group (n=165) of plasma samples by MSRED-qPCR.
Scatter plots of plasma levels of methylated SLC19A3 DNA in 60 healthy
normal subjects, 45 gastric cancer (GC) and 60 breast cancer (BC)
patients. Plasma level of methylated SLC19A3 DNA is expressed as
2
DCt(undigest-digest). DCt(undigest-digest) is calculated by subtracting the Ct
values of digested plasma DNA from the Ct values of undigested
plasma DNA. Since Ct of undigest should be #Ct of digest, the
expression level is ranging from 1 to 0. The horizontal black lines
denote the means. The blue errors bars denote the 6 standard
deviations (SD). Statistically significant differences were determined
using Mann-Whitney U tests, P,0.0001.
doi:10.1371/journal.pone.0022233.g004
Figure 5. The receiver operating characteristics (ROC) curve for
plasma methylated SLC19A3 DNA in the Phase II blinded
validation (n=78). (A) Area under curve (AUC) value was 89%. At
cutoff value of 0.41, sensitivity was 87% and specificity was 85% in
discriminating 39 breast cancer patients from 20 control subjects. (B)
Area under curve (AUC) value was 82%. At cutoff value of 0.41,
sensitivity was 85% and specificity was 85% in discriminating 20 gastric
cancer patients from 20 control subjects.
doi:10.1371/journal.pone.0022233.g005
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PLoS ONE | www.plosone.org 5 July 2011 | Volume 6 | Issue 7 | e22233Figure 6. Plasma methylated SLC19A3 DNA levels across tumor stages from both Phase I and II validation. (A) Box plot of plasma
methylated SLC19A3 DNA level in 80 NC, 27 ductal carcinoma in situ (DCIS) plus 71 BC patients across various TNM stages. (B) Box plot of plasma
methylated SLC19A3 DNA level in 80 NC and 65 GC patients across various TNM stages. The box represents the interquartile range and the line across
the box indicates the median value. Relative plasma level of methylated SLC19A3 DNA is expressed as 2
2DCt(Dig-Undig). DCt(Dig-Undig) is calculated by
subtracting the Ct values of digested plasma DNA from the Ct values of undigested plasma DNA. Statistically significant differences were determined
using Mann-Whitney tests.
doi:10.1371/journal.pone.0022233.g006
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